Rhenman & Partners Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-607,070	Closed	-$14.8M	–	98
2019 Q1	$14.8M	Sell	607,070 -90,300	-13%	-$1.88M	1.73%	22
2018 Q4	$9.94M	Sell	697,370 -71,000	-9%	-$1.08M	1.14%	42
2018 Q3	$11.7M	Buy	768,370 +45,000	+6%	+$690K	1.17%	41
2018 Q2	$12.1M	Buy	723,370 +21,900	+3%	+$348K	1.24%	39
2018 Q1	$11.4M	Buy	701,470 +198,411	+39%	+$3.18M	1.41%	32
2017 Q4	$6.44M	Sell	503,059 -146,941	-23%	-$1.67M	0.87%	48
2017 Q3	$8M	Buy	650,000 +225,000	+53%	+$2.09M	1.02%	38
2017 Q2	$3.56M	Buy	425,000 +75,000	+21%	+$613K	0.51%	68
2017 Q1	$3.13M	Sell	350,000 -200,000	-36%	-$2.13M	0.5%	67
2016 Q4	$4.83M	Hold	550,000	–	–	0.93%	42
2016 Q3	$3.71M	Buy	550,000 +180,000	+49%	+$696K	0.59%	59
2016 Q2	$1.32M	Hold	370,000	–	–	0.23%	84
2016 Q1	$1.09M	Hold	370,000	–	–	0.22%	86
2015 Q4	$1.56M	Hold	370,000	–	–	0.24%	89
2015 Q3	$1.69M	Hold	370,000	–	–	0.27%	83
2015 Q2	$2.67M	Sell	370,000 -30,000	-8%	-$221K	0.32%	88
2015 Q1	$2.95M	Sell	400,000 -145,000	-27%	-$1.03M	0.5%	72
2014 Q4	$2.58M	Buy	545,000 +165,801	+44%	+$656K	0.75%	56
2014 Q3	$1.35M	Buy	379,199 +50,000	+15%	+$197K	0.4%	88
2014 Q2	$1.5M	Hold	329,199	–	–	0.45%	74
2014 Q1	$1.55M	Sell	329,199 -30,801	-9%	-$155K	0.46%	75
2013 Q4	$1.8M	Buy	+360,000	New	+$1.96M	0.71%	60

Other funds holding ARRY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rhenman & Partners Asset Management's ARRY Position: Q2 2019 in Review

Rhenman & Partners Asset Management sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 607,070 shares — an estimated $14.8M sold.

Rhenman & Partners Asset Management first reported a position in ARRY in Q4 2013 and held it in 22 quarters. The position peaked at $14.8M in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

Rhenman & Partners Asset Management reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
Rhenman & Partners Asset Management sold 607,070 Array Biopharma Inc shares in Q2 2019, an estimated $14.8M.
Rhenman & Partners Asset Management first reported a position in Array Biopharma Inc in Q4 2013 and held it in 22 quarters.
Rhenman & Partners Asset Management's Array Biopharma Inc position peaked at $14.8M in Q1 2019.
319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2019, filed 22 Jul 2019.